HOME > TOP STORIES

TOP STORIES

REGULATORY Japan to Present Class-by-Class Generic Shares to Hit New Goals: Minister

March 18, 2024
REGULATORY Japan Begins Discussions on RSV Vaccines for National Immunization Program

March 15, 2024
BUSINESS Takeda Settles on Lower Pay Hike than 2023; Union Group Says Pharma Labor Talks Tougher than Others

March 15, 2024
REGULATORY PD-1/PD-L1, JAK Drugs to Be Exempt from Spillover Price Cuts: Chuikyo

March 14, 2024
REGULATORY Lagevrio, Kerendia Braced for Price Cuts after Cost-Effectiveness Assessment

March 14, 2024
REGULATORY Japan Needs Systemic Reform to Balance Universal Coverage and Access to Pricey Meds: LDP Health Affairs Chief

March 13, 2024
COMMENTARY With So Many of Its Demands Met, How Will Industry Oppose Off-Year Price Revisions in FY2025?

March 12, 2024
REGULATORY PMDA Looks to Rev Up Pediatric and Orphan Drug Initiatives in Next 5-Year Plan: Chief

March 11, 2024
ACADEMIA Expert Says RSV Shots Will Have Significant Clinical Impact, Urges Public Funding and NIP Inclusion

March 8, 2024
BUSINESS Eisai CEO Confident in Leqembi Uptake, Says 90% of US Hospital Targets to Adopt Med by March-End

March 8, 2024
BUSINESS Majority of Drug Makers “Somewhat Satisfied” with FY2024 Revision: Poll

March 7, 2024
BUSINESS Removal of PMP Company Indicators Most Popular Policy Change in FY2024 Reform: Poll

March 7, 2024
BUSINESS Tsumura Sees 24% Price Hike as Kampo Enjoys Boon in FY2024 Revision: Poll

March 6, 2024
REGULATORY Opdivo Faces 15% Slash in Spillover, Re-Pricing to Hit 23 Drugs in FY2024 Revision

March 5, 2024
REGULATORY Drug Prices Cut by 4.67% in FY2024 Revision, 314 APIs to Keep Full Prices with PMP

March 5, 2024
REGULATORY MHLW to Ask All Generic Makers in Japan to Execute Self-Inspections

March 4, 2024
BUSINESS Moderna Japan Taps Kazumasa Nagayama as New President

March 4, 2024
REGULATORY Generic Mergers, Product Consolidations Unlikely to Pose Antitrust Issue: FTC Official

March 1, 2024
REGULATORY MHLW Sets Out to Beef Up Inspector Skills with Nationwide Sharing of GMP Reports

February 29, 2024
BUSINESS Insmed Revs Up for Product Expansion in Japan, Arikayce Frontline Filing Set for 2026 with More to Follow

February 28, 2024

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…